Evidence map›Paper›PMID 31575423›Full record

Trial reportThe American journal of cardiology2019

Comparison of Frequency of Atherosclerotic Cardiovascular Disease Events Among Primary and Secondary Prevention Subgroups of the Systolic Blood Pressure Intervention Trial.

Timothy B Plante, Stephen P Juraschek, Neil A Zakai, Russell P Tracy, Mary Cushman

Abstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in The American journal of cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Timothy B PlanteDepartment of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont. Electronic address: Timothy.Plante@uvm.edu.
Stephen P JuraschekDepartment of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts.
Neil A ZakaiDepartment of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont; Department Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
Russell P TracyDepartment Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
Mary CushmanDepartment of Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont; Department Pathology and Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont.

Funding

Vitamin D, Subclinical Cardiovascular Disease, and Orthostatic Hypotension in Older AdultsK23HL135273 · NHLBI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI JURASCHEK, STEPHEN P · 2017 to 2021
$1.1M
NHLBI NIH HHS K23 HL135273NIA NIH HHS L30 AG051250
6 · The paper itself

Abstract

The Pooled Cohort Equation (PCE) predicts 10-year risk of first-time atherosclerotic cardiovascular disease (ASCVD) events and was incorporated in analyses of a primary and secondary prevention population in the Systolic Blood Pressure Intervention Trial (SPRINT). Whether PCE enhances risk prediction among secondary prevention populations is unknown. We sought to compare ASCVD events by level of PCE-predicted risk among primary and secondary prevention SPRINT populations. SPRINT randomized adults with hypertension and ≥1 CVD risk factor or previous CVD events to systolic blood pressure control targeting <120 mm Hg or 135 to 139 mm Hg. We calculated the hazard ratio (HR) of ASCVD events among secondary versus primary (reference) prevention subgroups overall and by predicted 10-year ASCVD risk categories (<10%, 10% to <20%, 20% to <30%, and ≥30%) and within risk subgroups, comparing to the lowest risk category. Among 8,151 participants, 16% with previous CVD, mean age was 66 years and 35% were women. The HR for ASCVD events overall was 2.51 (1.96, 3.20). HR was 2.97 (1.47, 5.99) among <10% 10-year risk and 2.23 (1.38, 3.59) among ≥30% risk. Within subgroups comparing ≥30% to <10% risk (reference) categories, the HR was 2.85 (1.76, 4.63) for primary and 2.14 (1.07, 4.30) for the secondary prevention. In conclusion, history of previous events was a potent risk factor for subsequent ASCVD events. The PCE does not enhance risk prediction among secondary prevention populations and may differentially underestimate risk in secondary prevention populations with lowest predicted risk.

Indexed as

ForecastingAgedAntihypertensive AgentsAtherosclerosisBlood PressureFemaleFollow-Up StudiesHumansHypertensionIncidenceMaleMiddle AgedPrimary PreventionRisk AssessmentRisk FactorsSecondary PreventionAntihypertensive Agents

Identifiers

PMID31575423
PMCPMC7240131

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.